Detail page

Knowledge Web

Person

David T. W. Jones

Name	David T. W. Jones
Place	Heidelberg (Wirkungsort) Deutschland
Gender	männlich
Academic degree	Dr.
Related	Deutsches Krebsforschungszentrum Universität Heidelberg. Medizinische Fakultät Klinikum Heidelberg Nationales Centrum für Tumorerkrankungen
Further information	Group leader Molekulare Diagnostik, Pädiatrische Neuroonkologie, NCT, Medizinische Fakultät Heidelberg, DKFZ
Record type	Person
GND-Identifier	1058669672
Record ID	1058669672
Involved in show all Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration Compartments in medulloblastoma with extensive nodularity are connected through differentiation along the granular precursor lineage Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours Group-specific cellular metabolism in Medulloblastoma Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome DNA methylation-based classification of sinonasal tumors Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM The genomic landscape of pediatric renal cell carcinomas GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1 Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1 Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1 Super enhancers define regulatory subtypes and cell identity in neuroblastoma Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data Genomic footprints of activated telomere maintenance mechanisms in cancer Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14 Genomic footprints of activated telomere maintenance mechanisms in cancer YAP1-fusions in pediatric NF2-wildtype meningioma Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations YAP1-fusions in pediatric NF2-wildtype meningioma Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course MYCN amplification drives an aggressive form of spinal ependymoma Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1 TelomereHunter – in silico estimation of telomere content and composition from cancer genomes Mutational patterns and regulatory networks in epigenetic subgroups of meningioma Molecular progression of SHH-activated medulloblastomas DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1–NFATc2 fusion from Ewing sarcoma Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA Challenges to curing primary brain tumours Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1 High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma Mutational patterns and regulatory networks in epigenetic subgroups of meningioma Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

David T. W. Jones

Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

Compartments in medulloblastoma with extensive nodularity are connected through differentiation along the granular precursor lineage

Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures

Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow

Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics

Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours

Group-specific cellular metabolism in Medulloblastoma

Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification

Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts

Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification

Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas

MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression

Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study

Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival

Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome

DNA methylation-based classification of sinonasal tumors

Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM

The genomic landscape of pediatric renal cell carcinomas

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors

Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1

Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1

Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation

PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors

Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1

Super enhancers define regulatory subtypes and cell identity in neuroblastoma

Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data

Genomic footprints of activated telomere maintenance mechanisms in cancer

Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14

Genomic footprints of activated telomere maintenance mechanisms in cancer

YAP1-fusions in pediatric NF2-wildtype meningioma

Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations

YAP1-fusions in pediatric NF2-wildtype meningioma

Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation

Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities

Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course

MYCN amplification drives an aggressive form of spinal ependymoma

Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions

Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1

TelomereHunter – in silico estimation of telomere content and composition from cancer genomes

Mutational patterns and regulatory networks in epigenetic subgroups of meningioma

Molecular progression of SHH-activated medulloblastomas

DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1–NFATc2 fusion from Ewing sarcoma

Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre

Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA

Challenges to curing primary brain tumours

Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1

High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma

Mutational patterns and regulatory networks in epigenetic subgroups of meningioma

Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location